Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
BuyCanadianInsulin.com Announces Availability of "Generic Semaglutide" Product Listing Starting at $199.99 Per Pen
1+ day, 23+ hour ago (63+ words) openPR.com BuyCanadianInsulin.com Announces Availability of "Generic Semaglutide" Product Listing Starting at $199.99 Per Pen Press release from: Getnews Permanent link to this press release: You can edit or delete your press release BuyCanadianInsulin.com Announces Availability of "Generic Semaglutide…...
Bora Pharmaceuticals and Onconic Therapeutics Sign Manufacturing Agreement to Support U.S. Clinical Development of JAQBO Tablets
2+ day, 8+ hour ago (183+ words) Bora to manufacture and package clinical trial drug product for JAQBO tablets as Onconic advances U.S. Phase 3 preparation for gastroesophageal reflux disease (GERD) Under the agreement, Bora’s newest OSD facility in Maple Grove, Minn., will also support quality control, stability testing,…...
Accord BioPharma Announces Commercial Availability of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)
2+ day, 14+ hour ago (734+ words) Jul 23, 2026, 08:05 ET Biosimilars strengthen access to treatment for certain bone health conditions. OSVYRTI is available at a wholesaler acquisition cost (WAC) of $1,800.41 per 60 mg/mL single-dose pre-filled syringe, and JUBEREQ at a WAC price of $3,311.75 per 120 mg/1.7 mL (70 mg/mL) single-dose…...
Will Semaglutide Prices Drop After 2026 Patent Expirations?
3+ day, 14+ hour ago (172+ words) Generic injectable semaglutide could cost as little as $28 per person-year after the initial patent expired in April 2026 — a fraction of current branded prices — and be available in about 162 countries by the end of 2026, covering roughly 69% of the global type 2 diabetes…...
Health regulator reviews 12 generic semaglutide applications. - Fullview | Telling empowering stories, South Africans want to hear
4+ day, 22+ hour ago (260+ words) South Africa’s health regulator is reviewing 12 applications for generic versions of semaglutide, the active ingredient in Novo Nordisk’s blockbuster diabetes and weight-loss medicines, it said on Tuesday. Novo’s patent on semaglutide — used in diabetes drug Ozempic and weight-loss treatment Wegovy…...
Aspen's Generic Ozempic Gets Health Canada Approval, Launch Hinges on Dr Reddy's API Supply
4+ day, 10+ hour ago (193+ words) Johannesburg: South Africa's Aspen Pharmacare said on Monday that its Canadian subsidiary had received regulatory approval from Health Canada for Aspen-Semaglutide, a generic version of Novo Nordisk's blockbuster diabetes drug Ozempic. Africa's biggest pharmaceutical company said in a statement that…...
South Africa regulator reviews 12 generic semaglutide applications
4+ day, 14+ hour ago (254+ words) JOHANNESBURG, July 21 (Reuters) – South Africa’s health regulator is reviewing 12 applications for generic versions of semaglutide, the active ingredient in Novo Nordisk’s blockbuster diabetes and weight-loss medicines, it said on Tuesday. Novo’s patent on semaglutide — used in diabetes drug Ozempic and…...
South African firm wins Health Canada nod for generic Ozempic
4+ day, 23+ hour ago (244+ words) Supply shortage from India keeps the cheaper diabetes drug off shelves until late October A generic version of Novo Nordisk's diabetes drug Ozempic has cleared Health Canada, though a supply shortage will keep it off Canadian shelves for months. South…...
South African pharma giant secures Canadian nod for generic Ozempic
4+ day, 15+ hour ago (444+ words) Home » South African pharma giant secures Canadian nod for generic Ozempic A Canadian subsidiary of the African pharma giant has received regulatory approval to distribute generic semaglutide. A Canadian subsidiary of Africa’s largest pharmaceutical company has officially received regulatory approval…...
Aspen Pharmacare wins Canada approval for generic Ozempic after Novo patent expiry
5+ day, 10+ hour ago (216+ words) JOHANNESBURG, July 20 (Reuters) – South Africa’s Aspen Pharmacare said on Monday that its Canadian subsidiary had received regulatory approval from Health Canada for Aspen-Semaglutide, a generic version of Novo Nordisk’s blockbuster diabetes drug Ozempic. Africa’s biggest pharmaceutical company said in a…...